Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
The company logo is outside the headquarters of Eli Lilly, Indianapolis, Indiana, March 17, 2024.
Scott Olson | Getty Images
Eli Lilly Thursday said the highest dose Daily obesity pill Patients helped to lose almost 12% of body weight, or approximately 27 pounds, in a late 72-week stage scenario, opened the way to the market.
The weight loss of the pill was 11.2%, regardless of interruptions.
The company’s shares fell by more than 7% in the negotiation of premartments on Thursday. Meanwhile, arches of rival Novo NordiskThe market also works to bring an obesity pill, jumping more than 7% on Thursday.
Some data on the wall street analysts expected of Oral Lilly’s Oral GLP-1, about 15% with hope to lose weight. Some doctors say that the results are comparable, but in general, it is slightly smaller, the level of weight loss seen Novo NordiskObesity, Wegoy’s Weekly GLP-1 injection.
Some doctors also warned the number of patients in the highest dose of the pill due to side effects, for any other reason.
However, other doctors praised the results and the potential of the pill to reach new patients, such as needles.
“The result of a oral agent is a strong and promising, doctor Jaime Almandoz, calling the doctor director of the Weight Wellness in the Southwestern Medical Center, calling weight loss” significant and clinically significant result “.
“Injectables have set a high bar, but the oral LPG-1 potential is strengthened to be transformative in the care of obesity, especially for patients to start or maintain injectable therapies,” he continued.
Mihail “Misha” Dr. Zilbermint, the director of the Medical Hospital of the Johns Hopkins Community, said the pills “potential of the game modifier, as long as people can withstand side effects.”
The results of the trial are among the studies closely observed in the annual pharmaceutical industry Positive data in April 3. From a phase test Analyze the experimental pill of patients in diabetes. Eli Lilly’s pill, Orflipron, is a closer step, converting a new alternative to balance-alternatives, drug loss and drugs with diabetes called GLP-1s with weight loss and diabetes.
Eli Lilly “The result is not empty with these results. It is a thesis for us,” despite the fact that the streets had “,” CEO David Ricks CNBC said “Squawk Box“Thursday.
“The goal was to create a spoken pill and create a huge scale, which was really for the market, and he had weight loss, competitive with other GLP-1s, and that’s what we got,” said Ricks. He added the percentage of pill weight loss to “most people with overweight”, and want to achieve what they want to achieve metabolic health.
Ricks said that Eli Lilly expects to send data to the end of the year, “hoping to launch the pill around the world this time.
The launch can basically change the space, it can help more patients access treatments and alleviate the poor supply of existing injections. The pill can be more comfortable and easier in the segment of Eli Lilly in its growing segment include Novo Nordisk, for marketing weight loss pills.
There are approximately 8 million patients injectable obesity and diabetes drugs, but it is likely that the benefits of about 170 million medicines, Ken Custer, president of cardiometabolic health, in an interview.
“To meet this request, we will need other options, small oral molecules like Orflipron, who use different production paths and also have a sophisticated supply chain to distribute patients,” he said.
Dr. Amy Sheer, the director of the University of Florida, hopes that they will be more expensive than existing injections, are more expensive for the devices that are mostly included. Said lower price can help you remove obstacles to join patients.
Many insurance still do not cover GLP-1S due to obesity. Wegovy and other drugs have prices about $ 1,000 before the insurance.
Specific trials
The highest dose of Eli Lilly’s pills loses 10% of patients by 10% of patients and 39% of patients lose at least 15% of the patient according to the results of the trial.
Almandoz said the proportion of people who have achieved the “greater magnitudes” of weight loss, “many people” adds “the proportion of people who achieve these high weight loss categories” and usually the weight loss is carefully located
Orforglipron helped reduce the factors of cardiovascular risk.
But some patients came by some patients who suffered a pile in the pilot, according to some estimates of analysts.
About 10.3% of patients who have taken the highest dose of the pill – 36 milligrams of interruptions due to side effects compared to 2.6% of those who have taken placebo. These side effects were mainly gastrointestinal, nausea and incidents, and are lightweight. 24% of those who have taken the most highly dose incident 33.7% and 23.1% had nausea and diarrhea, respectively.
In front of the data, Evan Seigerman Evan Market Evan Seigerman said that he hoped less than 10% of the highest dose of the pill, side effects and nausea and diarrhea.
More patients took the pill compared to the GLP-1s in the market, said Caroline Apovian, Director of the Weight Management Center of the Brigham and Women’s Hospital. Pause fees due to the lateral stage of the late stage of the week of the week of WEGOVY and Eli Lilly’s Obesity injection About 7% or less.
The almost quarter of the highest dose of the pill was interrupted for some reason, realizing that Orflipron’s enthusiasm must be temperature, “because we get all this excitement, and then the pill did not come out.
Why not clearly, in addition to side effects, patients interrupted the pill. The treatment has been suspended for almost 30% of a placebo.
Eli Lilly’s Ricks said that the company has no responsibility in the study.
“What we really want to see is that the drop rate of the medicine is less than the placebo and that is what we have seen here,” he said, referring to interruption rates for any reason.
Ricks added that ELI LILLY was looking for a rate of less than 12% due to secondary effects, with 8% and 12% rates with GLP-1 drugs.
“We’re in the middle,” he said. “Tracking rates in this category are not perfect in all chronic drug categories. But the drop of the drug pays attention, and here again, we direct it with the profile.”
The University of Florida said he does not believe that interrupt rates or side effects will be a factor to decide the doctor when the pill is prescribed.
A oral option believes that more doctors do more doctors to make patients more comfortable to patients. Some doctors are questionable to prescribe injections today, “Maybe he doesn’t know how to use patients how to use it,” he added.
Almandoz said the decision-prescribed decisions will depend on the patient’s needs and specific priorities, as well as access and availability. GLP-1 can be injectable priority for patients with patients with a higher level of weight loss or are cardiometric complications or health problems that create cardiovascular diseases and metabolic disorders.
But the oral LPP-1 cannot be the most suitable “that prioritize simplicity or comfort or have these logistical challenges with injections,” he said.
The specific results of the trial will be submitted in September at a European medical meeting and published in the reviewed journal published. The results of the three trial of the pill will be shared more this year, this year, from an examination of obese or overweight adults, and have type 2 diabetes.
Wegovy, Eli Lilly’s Pill, Orflipron and Novo Nordisk’s diabetes pill rybelsus is aimed at a hormone called GLP-1, weight loss and regulating blood sugar. But unlike these other medications, Eli Lilly’s pill is not a peptide medication. This means that it is easier to absorb the body and does not require a diet restriction like Rybelsus.
Eli Lilly currently has about three years before other drugs developing pills Pfizer, Astrazeneca, Roche, Therapeutics structure and Viking TherapeuticsGuggenheim analyst Seamus Fernandez before CNBC.
Some analysts deserve more than $ 150 million in the early 200s in the market. Oral LPP-1 could cost $ 50 billion, Fernandez said.
– CNBC’s Angelica Peebles helped this report.
